Researchers behind Alzheimer's study: GLP-1 drugs show great promise

Armed with data from a phase II trial testing the efficiency of Novo Nordisk's liraglutide on Alzheimer's patients, scientists say the given drug class shows great promise for combating the disease – even though the market shows disappointment on Novo's behalf.

Photo: George Frey/Reuters/Ritzau Scanpix

Few ailments have frustrated medical science and the pharmaceutical industry for years on end in the way Alzheimer's has, as many have tried – and failed – to develop just one efficient treatment for the disease.

For this reason, the so-called Elad trial, which tests Novo Nordisk's liraglutide, which by the name of Victoza is already a well-established treatment for type II diabetes, as a treatment for Alzheimer's disease.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs